EP 1620545 A4 20070704 - DISEASE PREVENTION AND VACCINATION FOLLOWING THYMIC REACTIVATION

Title (en)

DISEASE PREVENTION AND VACCINATION FOLLOWING THYMIC REACTIVATION

Title (de)

KRANKHEITSVORBEUGUNG UND IMPFUNG NACH THYMUSREAKTIVIERUNG

Title (fr)

PRVENTION CONTRE UNE MALADIE ET VACCINATION APRES REACTIVATION THYMIQUE

Publication

EP 1620545 A4 20070704 (EN)

Application

EP 04759971 A 20040419

Priority

US 2004011913 W 20040419
US 41906803 A 20030418
US 41906603 A 20030418
US 41872703 A 20030418
US 41874703 A 20030418
US 52700103 P 20031205
US 74883103 A 20031230
US 74911803 A 20031230
US 74912203 A 20031230
US 74845003 A 20031230

Abstract (en)

[origin: WO2004094599A2] The present disclosure provides methods for preventing or treating illness, improving responsiveness to immunization, and improving the efficacy of gene therapy in a patient, by disrupting sex steroid mediated signaling and reactivating the patient's thymus. In some embodiments, the patient's thymus is reactivated by interruption or ablation of sex steroid mediated signaling by the administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines, anti-androgens, anti-estrogens, selective estrogen receptor modulators (SERMs), selective androgen receptor modulators (SARMs), selective progesterone response modulators (SPRMs), ERDs, aromatase inhibitors, or various combinations thereof.

IPC 8 full level

A01N 25/00 (2006.01); A61K 31/00 (2006.01); A61K 35/14 (2006.01); A61K 35/26 (2006.01); A61K 35/28 (2015.01); A61K 35/36 (2015.01); A61K 38/18 (2006.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01); A61K 39/38 (2006.01); A61K 45/06 (2006.01); A61K 48/00 (2006.01); A61P 31/00 (2006.01); A61P 31/12 (2006.01); A61P 31/18 (2006.01); A61P 37/00 (2006.01); A61P 37/04 (2006.01); A61P 37/06 (2006.01); C12N 5/02 (2006.01); F22B 7/04 (2006.01)

IPC 8 main group level

A61K (2006.01); C12N (2006.01)

CPC (source: EP KR)

A61K 31/00 (2013.01 - EP); A61K 35/26 (2013.01 - KR); A61K 35/28 (2013.01 - EP KR); A61K 35/36 (2013.01 - EP); A61K 38/09 (2013.01 - EP); A61K 38/18 (2013.01 - EP); A61K 38/1825 (2013.01 - EP); A61K 38/193 (2013.01 - EP); A61K 38/20 (2013.01 - EP); A61K 39/00 (2013.01 - EP KR); A61K 39/461 (2023.05 - EP KR); A61K 39/4615 (2023.05 - EP KR); A61K 39/4621 (2023.05 - EP KR); A61K 39/4622 (2023.05 - EP KR); A61K 39/46433 (2023.05 - EP KR); A61K 39/46434 (2023.05 - EP KR); A61K 39/46447 (2023.05 - EP KR); A61K 39/464493 (2023.05 - EP KR); A61K 39/464714 (2023.05 - EP KR); A61K 39/464817 (2023.05 - EP KR); A61K 39/464838 (2023.05 - EP KR); A61K 39/464839 (2023.05 - EP KR); A61K 45/06 (2013.01 - EP); A61K 48/0083 (2013.01 - EP); A61P 5/28 (2018.01 - EP); A61P 5/32 (2018.01 - EP); A61P 5/36 (2018.01 - EP); A61P 5/38 (2018.01 - EP); A61P 5/42 (2018.01 - EP); A61P 7/00 (2018.01 - EP); A61P 31/00 (2018.01 - EP); A61P 31/04 (2018.01 - EP); A61P 31/10 (2018.01 - EP); A61P 31/12 (2018.01 - EP); A61P 31/16 (2018.01 - EP); A61P 31/18 (2018.01 - EP); A61P 31/22 (2018.01 - EP); A61P 33/02 (2018.01 - EP); A61P 33/10 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 37/00 (2018.01 - EP); A61P 37/04 (2018.01 - EP); A61P 37/06 (2018.01 - EP); A61P 37/08 (2018.01 - EP); A61P 43/00 (2018.01 - EP); A61K 2239/31 (2023.05 - EP KR); A61K 2239/38 (2023.05 - EP KR); A61K 2239/59 (2023.05 - EP KR); Y02A 50/30 (2018.01 - EP)

C-Set (source: EP)

Citation (search report)

[X] WO 0230259 A2 20020418 - BOYD RICHARD [AU]
[X] WO 0230320 A2 20020418 - BOYD RICHARD [AU]
[E] WO 2004103271 A2 20041202 - NORWOOD IMMUNOLOGY LTD [AU], et al & BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), 44TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; PHILADELPHIA, PA, USA; DECEMBER 06-10, 2002, pages Abstract No. 1578, ISSN: 0006-4971 & BLOOD, vol. 102, no. 11, 16 November 2003 (2003-11-16), 45TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 06-09, 2003, pages 527a, ISSN: 0006-4971 & BLOOD, vol. 102, no. 11, 16 November 2003 (2003-11-16), 45TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 06-09, 2003, pages 77a, ISSN: 0006-4971
[X] DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2002 (2002-11-16), GOLDBERG GABRIELLE L ET AL: "Sex Steroid Ablation Enhances Immune Reconstitution Following Allogeneic Bone Marrow Transplantation.", XP002431952, Database accession no. PREV200300336178
[PX] DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2003 (2003-11-16), SUTHERLAND JAYNE S ET AL: "Sex steroid ablation therapy enhances hemopoiesis and lymphopoiesis following allogeneic and autologous peripheral blood stem cell transplantation.", XP002431953, Database accession no. PREV200400147250
[PA] DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2003 (2003-11-16), SCHWARER ANTHONY P ET AL: "Sex steroid suppression with luteinizing hormone releasing hormone agonist (LHRH-A) allows thymic reactivation and improved immunological recovery after allogeneic hematopoietic stem cell transplantation (alloHSCT).", XP002431954, Database accession no. PREV200400172459

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2004094599 A2 20041104; WO 2004094599 A3 20051229; AU 2004241949 A1 20041202; CA 2528521 A1 20041202; EP 1620126 A2 20060201; EP 1620126 A4 20070704; EP 1620545 A2 20060201; EP 1620545 A4 20070704; JP 2007518699 A 20070712; KR 20060022232 A 20060309; WO 2004103271 A2 20041202; WO 2004103271 A3 20051124

DOCDB simple family (application)

US 2004011913 W 20040419; AU 2004241949 A 20040419; CA 2528521 A 20040419; EP 04759971 A 20040419; EP 04785486 A 20040419; JP 2006532426 A 20040419; KR 20057019858 A 20051018; US 2004011921 W 20040419